Red Tree Reveals First West Coast VC Fund As It Readies For Second

San Francisco Firm Saw Unmet Funding Need

Red Tree Venture Capital closed its first fund with $272m for biotech companies emerging from academic and research institutions, seeking to fill a need for early-stage funding on the West Coast.

VC Venture Capital, acronym text concept on blackboard — Red Tree focuses on West Coast start-ups emerging from academia • Source: Shutterstock

Red Tree Venture Capital hopes to provide early-stage VC funding to life science start-ups emerging from academic and research institutions on the West Coast – funding that, the firm believes, has been lacking relative to funding for innovation coming out of East Coast institutions.

Demand for Red Tree’s capital so far has shown that there is a need for the kind of early-stage funding it can provide. The VC firm launched at the start...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

23 May 2025

• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

22 May 2025

• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

21 May 2025

• By Mandy Jackson

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

20 May 2025

• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

22 May 2025

• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.